Summer 2020 Vol. 10 Issue 02
-
From the Editor-in-Chief
Measuring a Cancer Drug’s EffectivenessSurrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?
by William G. Nelson, MD, PhD
-
Your Cancer Guide
Not Our First RodeoDuring the COVID-19 pandemic, cancer survivors can tap into familiar lessons of resiliency.
by Hester Hill Schnipper
-
Caregiving With Confidence
The Power of AngerAccepting this emotion can be the first step in channeling it for a constructive purpose.
by Karen J. Bannan
-
Policy Matters
Racial and Ethnic Disparities in Multiple Myeloma Clinical TrialsThe AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.
by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD
-
A Delicate Balance
Cancer patients with chronic pain and the physicians who treat them strive to address pain while avoiding potential opioid abuse and addiction.
by Charlotte Huff
-
Keeping CLL in Check
With recent advances in targeted treatments, people diagnosed with chronic lymphocytic leukemia have more options to manage the disease.
by Kendall K. Morgan
-
Robotic Surgery and Cancer
Using robotic assistants for cancer surgery has become commonplace. Whether cancer patients benefit when a surgeon uses a robot remains unclear.
by Sue Rochman
-
Survivor Profile
Sharing Her StrengthDiagnosed with two cancers prior to turning 40, Rebecca Esparza uses her voice to advocate for policy changes to help people affected by cancer.
by Lindsey Konkel
-
Q&A
Taking the Long ViewIn her first book, journalist and breast cancer survivor Kate Pickert traces the winding road of cancer research and patient advocacy.
by Marci A. Landsmann
-
Sound Advice
Your Questions, Our AnswersWeight gain during treatment, conversations about sex, and what to know about a loved one's insurance.
-
Facts and Stats
A Quarter Century of Progress Against Lung CancerWhile advances have been made in treating lung cancer and risk reduction, there is still plenty of work to be done.
by Bradley Jones
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona